share_log

華潤醫藥：公告江中藥業2024年12月31日止年度的主要財務資料

CHINARES PHARMA: ANNOUNCEMENTPRINCIPAL FINANCIAL INFORMATION OFJIANGZHONG PHARMACEUTICALFOR THE YEAR ENDED 31 DECEMBER 2024

HKEX ·  Mar 19 12:45

Summary by Moomoo AI

江中藥業發佈2024年度業績報告，營業總收入為人民幣44.35億元，同比下降2.59%；上市公司股東應佔淨利潤為人民幣7.88億元，同比增長9.67%。每股基本盈利為人民幣1.25元，加權平均資產淨值回報率達19.58%。公司總資產達人民幣65.08億元，同比增長1.66%；上市公司股東應佔資產淨值為人民幣38.63億元，同比下降1.20%。經營活動所得現金流量淨額為人民幣7.86億元，同比下降24.36%。董事會建議以實施權益分派股權登記日總股本為基數，向全體股東派發現金股息，每10股派發人民幣7.00元（含稅），該建議將提交2024年股東週年大會審議。
江中藥業發佈2024年度業績報告，營業總收入為人民幣44.35億元，同比下降2.59%；上市公司股東應佔淨利潤為人民幣7.88億元，同比增長9.67%。每股基本盈利為人民幣1.25元，加權平均資產淨值回報率達19.58%。公司總資產達人民幣65.08億元，同比增長1.66%；上市公司股東應佔資產淨值為人民幣38.63億元，同比下降1.20%。經營活動所得現金流量淨額為人民幣7.86億元，同比下降24.36%。董事會建議以實施權益分派股權登記日總股本為基數，向全體股東派發現金股息，每10股派發人民幣7.00元（含稅），該建議將提交2024年股東週年大會審議。
Jiangzhong Pharmaceutical released its 2024 annual performance report, with total operating revenue of 4.435 billion yuan, a year-on-year decrease of 2.59%; the net profit attributable to shareholders of the listed company was 0.788 billion yuan, an increase of 9.67% year-on-year. The basic earnings per share were 1.25 yuan, and the weighted average ROI reached 19.58%.The company's total assets reached 6.508 billion yuan, a year-on-year increase of 1.66%; the net assets attributable to shareholders of the listed company were 3.863 billion yuan, a year-on-year decrease of 1.20%. The net cash flow from operating activities was 0.786 billion yuan, a year-on-year decrease of 24.36%.The Board of Directors proposed to distribute a cash dividend to all shareholders based on the total share capital as of the equity distribution registration date, distributing 7.00 yuan (tax included) for every 10 shares. This proposal will be submitted for discussion at the 2024 Annual General Meeting of Shareholders.
Jiangzhong Pharmaceutical released its 2024 annual performance report, with total operating revenue of 4.435 billion yuan, a year-on-year decrease of 2.59%; the net profit attributable to shareholders of the listed company was 0.788 billion yuan, an increase of 9.67% year-on-year. The basic earnings per share were 1.25 yuan, and the weighted average ROI reached 19.58%.The company's total assets reached 6.508 billion yuan, a year-on-year increase of 1.66%; the net assets attributable to shareholders of the listed company were 3.863 billion yuan, a year-on-year decrease of 1.20%. The net cash flow from operating activities was 0.786 billion yuan, a year-on-year decrease of 24.36%.The Board of Directors proposed to distribute a cash dividend to all shareholders based on the total share capital as of the equity distribution registration date, distributing 7.00 yuan (tax included) for every 10 shares. This proposal will be submitted for discussion at the 2024 Annual General Meeting of Shareholders.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 328

Recommended

Related Stocks Related Stocks
Symbol Mini Chart Price
SANAI HEALTH GP
01889
0.270
TIANDA PHARMA
00455
0.180
ZHONGZHIPHARM
03737
0.940
NT PHARMA
01011
0.255
AIM VACCINE
06660
4.400
Log In for the Full List
Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina Show More
Can strong earnings reports drive Chinese concept stocks to continue rising?
77%
23%
Bullish
Bearish
1500 votes
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
On Tuesday, China's political leadership is convening at the Great Hall of the People in Beijing for the year's most significant event, known as the "Two Sessions." These closed-door meetings are the annual plenary sessions of both the National People's Congress and the Chinese People's Political Consultative Conference, typically held simultaneously in March. The sessions generally last for about ten days....

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
OK